Drugs / peptide specific dendritic cell
peptide specific dendritic cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03291444 | May 2018 → Dec 2024 | acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome | Zhujiang Hospital | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | peptide specific dendritic cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03291444 ↗ |
| Modality | Vaccine | “Dendritic cell vaccines extend CAR T-cell persistence and improve the efficacy of CD19 CAR T-cell therapy in refractory or relapsed adult B-ALL patients.” PMID 38712616 ↗ May 2024 |
| Route | Other | “After transfusion of chimeric antigen receptor T cells, Eps8 or WT1 peptide specific dendritic cell were intradermal injected.” NCT03291444 ↗ |
| Target | WT1 | “After transfusion of chimeric antigen receptor T cells, Eps8 or WT1 peptide specific dendritic cell were intradermal injected.” NCT03291444 ↗ |